Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | AURKA | O14965 | 4/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13331409 | 0.84 | EGFR (0.84) | EGFRAURKA | |
| SCHEMBL13331179 | 0.84 | EGFR (0.79) | EGFRAURKACHEK1MAP2K1KMT2A | |
| SCHEMBL13331172 | 0.84 | EGFR (0.79) | EGFRAURKACHEK1MAP2K1KMT2A | |
| SCHEMBL13331144 | 0.82 | EGFR (1.00) | EGFRAURKA | |
| SCHEMBL13331166 | 0.82 | EGFR (0.80) | EGFRAURKACHEK1MAP2K1 | |
| SCHEMBL3318726 | 0.82 | EGFR (1.00) | EGFRAURKA | |
| SCHEMBL2249401 | 0.81 | AURKA (0.83) | EGFRAURKACHEK1MAP2K1KMT2A | |
| SCHEMBL13331411 | 0.81 | EGFR (1.00) | EGFR | |
| SCHEMBL13331165 | 0.81 | EGFR (1.00) | EGFRAURKACHEK1MAP2K1 | |
| SCHEMBL13331167 | 0.80 | EGFR (0.77) | EGFRAURKACHEK1MAP2K1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187389-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-08-25 | — | — | US | disclosed |
| WO-2005067546-A2 | PYRROLOPYRIMIDINE DERIVATIVES AND ANALOGS AND THEIR USE IN THE TREATMENT AND PREVENTION OF DISEASES | AMBIT BIOSCIENCES CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050153989-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187389-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | EGFR 3080/4885AURKA 1416/4885CHEK1 210/4885 |
| US-20050153989-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | EGFR 3080/4885AURKA 1416/4885CHEK1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.